Related Experiment Videos
Pulmonary hypertension in interstitial lung disease
Charlie Strange1, Kristin B Highland
1Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, USA. strangec@musc.edu
Current Opinion in Pulmonary Medicine
|August 12, 2005
Summary
Treating pulmonary hypertension in interstitial lung disease may improve exercise capacity. Early studies show promise, suggesting larger trials are needed for these antifibrotic therapies.
Area of Science:
- Pulmonary Medicine
- Cardiology
- Respiratory Research
Background:
- Interstitial lung disease (ILD) frequently causes exercise impairment and pulmonary hypertension (PH).
- Current antifibrotic therapies for ILD lack definitive proof of efficacy.
- Focus is shifting towards managing pulmonary vascular complications in ILD.
Purpose of the Study:
- To review the current understanding of pulmonary hypertension in interstitial lung disease.
- To explore the relationship between exercise impairment, pulmonary hypertension, and survival in ILD.
- To assess the potential benefits of treating pulmonary hypertension in ILD patients.
Main Methods:
- Review of existing literature on exercise impairment and PH in ILD.
- Analysis of correlations between pulmonary artery pressure, exercise, hypoxemia, and survival.
- Evaluation of outcomes from small case series of PH treatment in ILD.
Main Results:
- Pulmonary artery pressure often elevates with exercise in idiopathic pulmonary fibrosis (IPF).
- Exercise impairment in IPF strongly correlates with elevated pulmonary artery pressure.
- Hypoxemia, a marker of PH, is a significant predictor of survival in IPF.
Conclusions:
- Small case series indicate potential improvement in patients receiving PH therapy for ILD.
- Larger clinical trials are warranted to investigate targeted PH medications in ILD.
- Managing PH may be a viable strategy for improving outcomes in interstitial lung disease.